|
IL89220A
(en)
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5977316A
(en)
|
1995-01-17 |
1999-11-02 |
The Board Of Trustees Of The University Of Kentucky |
Monoclonal antibody 1A7 and related polypeptides
|
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
JP4776843B2
(ja)
|
1999-10-01 |
2011-09-21 |
イムノゲン インコーポレーティッド |
免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
|
|
JP2004502742A
(ja)
|
2000-07-12 |
2004-01-29 |
アイデック ファーマスーティカルズ コーポレイション |
Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
CA2436180C
(en)
|
2001-01-31 |
2011-11-08 |
Idec Pharmaceutical Corporation |
Immunoregulatory antibodies and uses thereof
|
|
US20030103971A1
(en)
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
WO2002060484A1
(en)
|
2001-01-31 |
2002-08-08 |
Idec Pharmaceuticals Corporation |
Use of cd23 antagonists for the treatment of neoplastic disorders
|
|
IL159177A0
(en)
|
2001-06-20 |
2004-06-01 |
Prochon Biotech Ltd |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
AU2002349727B2
(en)
|
2001-11-08 |
2008-10-16 |
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd |
Hepatitis E virus monoclonal antibodies or the binding fragments of it and the use thereof
|
|
ATE420964T1
(de)
|
2001-11-16 |
2009-01-15 |
Biogen Idec Inc |
Polycistronische expression von antikörpern in cho zellen
|
|
AU2003283599C1
(en)
|
2002-11-15 |
2009-06-25 |
Immunomedics, Inc. |
Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
|
|
CA2508831C
(en)
|
2002-12-13 |
2012-05-01 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
KR101351122B1
(ko)
|
2003-05-09 |
2014-01-14 |
듀크 유니버시티 |
Ｃｄ２０-특이적 항체 및 이를 이용한 방법
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
US7241598B2
(en)
*
|
2004-06-29 |
2007-07-10 |
The Chinese University Of Hong Kong |
Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
|
|
US7371825B2
(en)
*
|
2004-06-30 |
2008-05-13 |
Centocor, Inc. |
Anti-MCP-1 antibodies, compositions, methods and uses
|
|
CA2593212A1
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
|
EP1851248B1
(en)
|
2005-02-10 |
2016-08-10 |
Baylor Research Institute |
Anti-interferon alpha monoclonal antibodies and methods for use
|
|
US8318906B2
(en)
|
2005-04-15 |
2012-11-27 |
The Regents Of The University Of California |
EMP2 antibodies and their therapeutic uses
|
|
WO2006117910A1
(ja)
*
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
|
US7601335B2
(en)
|
2005-05-20 |
2009-10-13 |
Genentech, Inc. |
Pretreatment of a biological sample from an autoimmune disease subject
|
|
EP1904101A4
(en)
|
2005-06-08 |
2011-06-15 |
Univ Duke |
ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
|
|
US20080279850A1
(en)
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
AU2006272555B2
(en)
*
|
2005-07-25 |
2012-03-08 |
Aptevo Research And Development Llc |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
PT2032606E
(pt)
|
2006-05-30 |
2014-02-05 |
Genentech Inc |
Anticorpos e imunoconjugados e respetivas utilizações
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
WO2008019061A2
(en)
|
2006-08-03 |
2008-02-14 |
Vaccinex, Inc. |
Anti-il-6 monoclonal antibodies and uses thereof
|
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
|
CA2663536A1
(en)
|
2006-10-24 |
2008-05-02 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
WO2009023386A2
(en)
|
2007-07-06 |
2009-02-19 |
Trubion Pharmaceuticals, Inc. |
Binding peptides having a c-terminally disposed specific binding domain
|
|
PE20090499A1
(es)
|
2007-08-09 |
2009-05-18 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
GB2454915B
(en)
|
2007-11-23 |
2012-02-15 |
Schlumberger Holdings |
Spooling apparatus for well intervention system
|
|
WO2009085576A2
(en)
|
2007-12-28 |
2009-07-09 |
Spring Bioscience Corporation |
Positive control cell pellets for immunohistochemistry and methods of use thereof
|
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
US7740844B2
(en)
|
2008-04-29 |
2010-06-22 |
Taiwan Liposome Co. Ltd |
Anti-VEGF monoclonal antibody
|
|
NZ588884A
(en)
|
2008-04-30 |
2013-05-31 |
Immunogen Inc |
Cross-linkers and their uses
|
|
KR20110028450A
(ko)
|
2008-06-16 |
2011-03-18 |
이뮤노젠 아이엔씨 |
새로운 상승 효과
|
|
AU2009270988A1
(en)
|
2008-07-15 |
2010-01-21 |
Genentech, Inc. |
Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
|
|
AU2009313877A1
(en)
|
2008-11-13 |
2011-06-30 |
Emergent Product Development Seattle, Llc |
CD37 immunotherapeutic combination therapies and uses thereof
|
|
CN102596922A
(zh)
|
2009-10-06 |
2012-07-18 |
免疫基因公司 |
有效的缀合物和亲水性连接体
|
|
US20130089554A1
(en)
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
|
WO2011100398A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc. |
Cd20 antibodies and uses thereof
|
|
AR080154A1
(es)
|
2010-02-10 |
2012-03-14 |
Immunogen Inc |
Anticuerpos cd20 y su utilizacion
|
|
LT2544719T
(lt)
|
2010-03-12 |
2019-10-25 |
Debiopharm Int Sa |
Cd37 surišančios molekulės, ir jų imunokonjugatai
|
|
KR20130108069A
(ko)
|
2010-04-15 |
2013-10-02 |
알퍼 바이오테크, 엘엘씨 |
Ｈｅｒ2 항원에 대한 모노클로날 항체 및 그를 위한 용도
|
|
EA033468B1
(ru)
|
2011-03-29 |
2019-10-31 |
Immunogen Inc |
Способы получения конъюгата "антитело-майтансиноид"
|
|
AU2012236210B2
(en)
|
2011-04-01 |
2016-02-04 |
Immunogen, Inc. |
CD37-binding molecules and immunoconjugates thereof
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
EP3272364B1
(en)
|
2011-12-13 |
2020-07-29 |
Nordic Nanovector ASA |
Chimeric therapeutic anti-cd37 antibodie hh1
|
|
RU2014140119A
(ru)
*
|
2012-03-30 |
2016-05-27 |
Иммьюноджен, Инк. |
Способы повышения эффективности терапии на основе cd37
|
|
WO2013171289A1
(en)
|
2012-05-16 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Combination of cd37 antibodies with further agents
|
|
US20140120083A1
(en)
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
WO2014143807A2
(en)
|
2013-03-15 |
2014-09-18 |
Stromatt Scott |
Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
|
|
BR112015030457A2
(pt)
|
2013-06-07 |
2017-08-22 |
Nordic Nanovector As |
Método para regular positivamente a expressão de antígeno
|
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
CA2926893C
(en)
|
2013-11-07 |
2022-04-12 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti cd20 antibody with a btk inhibitor
|
|
WO2015116729A2
(en)
|
2014-01-28 |
2015-08-06 |
Emergent Product Development Seattle, Llc |
Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
|
|
WO2015175533A2
(en)
|
2014-05-13 |
2015-11-19 |
Immunogen, Inc. |
Anti-cd37 immunoconjugate dosing regimens
|
|
BR112017026027A2
(pt)
|
2015-06-08 |
2018-08-14 |
Debiopharm Int Sa |
combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
|
|
JP6890581B2
(ja)
|
2015-08-28 |
2021-06-18 |
デビオファーム インターナショナル， エス． アー． |
Ｃｄ３７の検出のための抗体およびアッセイ
|
|
US11278629B2
(en)
|
2016-11-02 |
2022-03-22 |
Debiopharm International, S.A. |
Methods for improving anti-CD37 immunoconjugate therapy
|
|
AU2019277836A1
(en)
|
2018-05-30 |
2021-01-21 |
Debiopharm International, S.A. |
Anti-CD37 immunoconjugate dosing regimens
|